Modulation of eIF4E expression

Details for Australian Patent Application No. 2004274942 (hide)

Owner Eli Lilly and Company Isis Pharmaceuticals, Inc.

Inventors Dobie, Kenneth W.; Bhat, Balkrishen; Swayze, Eric E.; Graff, Jeremy R.; Marcusson, Eric G.

Agent Spruson & Ferguson

Pub. Number AU-B-2004274942

PCT Pub. Number WO2005/028628

Priority 60/576,534 03.06.04 US; 60/504,110 18.09.03 US

Filing date 17 September 2004

Wipo publication date 31 March 2005

Acceptance publication date 28 February 2008

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

9 March 2006 PCT application entered the National Phase

  PCT publication WO2005/028628 Priority application(s): WO2005/028628

7 February 2008 Amendment Made

  The nature of the amendment is: Amend the name of the coinventors to delete Freier, Susan M. and Konicek, Bruce W. 2005

28 February 2008 Application Accepted

  Published as AU-B-2004274942

26 June 2008 Standard Patent Sealed

3 June 2010 Assignment Registered

  Eli Lilly and Company; Isis Pharmaceuticals, Inc. The patent has been assigned to Isis Pharmaceuticals, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004274951-RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

2004274940-Methods and compositions for enhanced plant cell transformation